GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thor Medical ASA (LTS:0R6Y) » Definitions » Total Liabilities

Thor Medical ASA (LTS:0R6Y) Total Liabilities : kr58.91 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Thor Medical ASA Total Liabilities?

Thor Medical ASA's Total Liabilities for the quarter that ended in Dec. 2023 was kr58.91 Mil.

Thor Medical ASA's quarterly Total Liabilities declined from Dec. 2022 (kr45.80 Mil) to Jun. 2023 (kr20.70 Mil) but then increased from Jun. 2023 (kr20.70 Mil) to Dec. 2023 (kr58.91 Mil).

Thor Medical ASA's annual Total Liabilities declined from Dec. 2021 (kr156.16 Mil) to Dec. 2022 (kr45.80 Mil) but then increased from Dec. 2022 (kr45.80 Mil) to Dec. 2023 (kr58.91 Mil).


Thor Medical ASA Total Liabilities Historical Data

The historical data trend for Thor Medical ASA's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thor Medical ASA Total Liabilities Chart

Thor Medical ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 127.71 135.94 156.16 45.80 58.91

Thor Medical ASA Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.12 129.02 45.80 20.70 58.91

Thor Medical ASA Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Thor Medical ASA's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.446+(0+54.464
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=58.91

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=330.835-271.925
=58.91

Thor Medical ASA's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.446+(0+54.464
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=58.91

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=330.835-271.925
=58.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thor Medical ASA Total Liabilities Related Terms

Thank you for viewing the detailed overview of Thor Medical ASA's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Thor Medical ASA (LTS:0R6Y) Business Description

Traded in Other Exchanges
Address
Kjelsasveien 168 B, Oslo, NOR, 0884
Nordic Nanovector ASA is a biopharmaceutical company. It is engaged in the development and commercialization of targeted therapeutics to improve the lives of patients with haematological cancers, such as non-Hodgkin lymphoma and leukaemia. The company's main clinical stage product is Betalutin.

Thor Medical ASA (LTS:0R6Y) Headlines

No Headlines